Patient-Oriented Evidence That Matters
Mifepristone Pretreatment Improves Success Rate of Misoprostol for Early Pregnancy Loss
Am Fam Physician. 2018 Dec 1;98(11):683-684.
In women with early pregnancy loss, does pretreatment with mifepristone (Mifeprex) before misoprostol (Cytotec) improve outcomes over treatment with misoprostol alone?
In women with early pregnancy loss between five and 12 weeks' gestation, pretreatment with 200 mcg of oral mifepristone before 800 mcg of vaginal misoprostol increases the likelihood of successful expulsion of the gestational sac (number needed to treat [NNT] = 6). (Level of Evidence = 1b–)
The researchers recruited adult women who had a closed cervical os and an ultrasound that showed a nonviable intrauterine pregnancy between five and 12 weeks' gestation. They excluded women with an open cervical os or no visible gestational sac, anemia, a viable or ectopic pregnancy, or any contraindication to the study medications. The mean age of the 300 participants was 30 years, 44% were black, and most had a six- to eight-week gestation. Women were randomized to receive directly observed therapy with oral mifepristone, 200 mcg, followed by 800 mcg of misoprostol (four tablets) inserted vaginally 24 hours later, or to the misoprostol alone. Although women and their physicians were not masked to the treatment assigned, the person assessing the ultrasound was masked. Each woman had a follow-up visit at one to four days, and if a gestational sac was present on the ultrasound, she was offered a second dose of misoprostol or the option of surgical evacuation, with follow-up approximately one week after that. All women had a final follow-up visit at one month. Only seven women were lost to follow-up or withdrew consent in each group. The likelihood of expulsion at the initial follow-up visit was significantly higher with the combination therapy (84% vs. 67%; 95% confidence interval for the difference, 7% to 26%; NNT = 6). Women who did not follow instructions and took the misoprostol fewer than 18 hours after the mifepristone had a somewhat lower likelihood of success (80% vs. 87%;
Editor's Note: Dr. Mark H. Ebell is Deputy Editor for Evidence-Based Medicine in AFP and cofounder and Editor-in-Chief of Essential Evidence Plus, published by Wiley-Blackwell, Inc. Dr. Allen F. Shaughnessy is an Assistant Medical Editor for AFP.
POEMs (patient-oriented evidence that matters) are provided by Essential Evidence Plus, a point-of-care clinical decision support system published by Wiley-Blackwell. For more information, see http://www.essentialevidenceplus.com. Copyright Wiley-Blackwell. Used with permission.
For definitions of levels of evidence used in POEMs, see http://www.essentialevidenceplus.com/product/ebm_loe.cfm?show=oxford.
To subscribe to a free podcast of these and other POEMs that appear in AFP, search in iTunes for “POEM of the Week” or go to http://goo.gl/3niWXb.
This series is coordinated by Sumi Sexton, MD, Editor-in-Chief.
A collection of POEMs published in AFP is available at https://www.aafp.org/afp/poems.
Want to use this article elsewhere? Get Permissions